ClinicalTrials.gov record
Recruiting Phase 3 Interventional

Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

ClinicalTrials.gov ID: NCT05303064

Public ClinicalTrials.gov record NCT05303064. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 7, 2026, 9:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth)

Study identification

NCT ID
NCT05303064
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Alkermes, Inc.
Industry
Enrollment
220 participants

Conditions and interventions

Interventions

  • OLZ/SAM Drug
  • Olanzapine Drug

Drug

Eligibility (public fields only)

Age range
10 Years to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 29, 2022
Primary completion
Aug 31, 2026
Completion
Aug 31, 2026
Last update posted
May 5, 2026

2022 – 2026

United States locations

U.S. sites
26
U.S. states
19
U.S. cities
26
Facility City State ZIP Site status
Alkermes Investigator Site Dothan Alabama 36303 Recruiting
Alkermes Investigator Site Little Rock Arkansas 72204 Recruiting
Alkermes Investigator Site Encino California 91316 Withdrawn
Alkermes Investigator Site Stanford California 94305 Recruiting
Alkermes Investigator Site Upland California 91786 Withdrawn
Alkermes Investigator Site Colorado Springs Colorado 80910 Withdrawn
Alkermes Investigator Site Denver Colorado 80202 Active, not recruiting
Alkermes Investigator Site Hartford Connecticut 06106 Withdrawn
Alkermes Investigator Site Washington D.C. District of Columbia 20010 Recruiting
Alkermes Investigator Site Miami Florida 33155 Withdrawn
Alkermes Investigator Site Miami Lakes Florida 33016 Recruiting
Alkermes Investigator Site Decatur Georgia 30030 Recruiting
Alkermes Investigator Site Chicago Illinois 60611 Recruiting
Alkermes Investigator Site Indianapolis Indiana 46202 Recruiting
Alkermes Investigator Site Saint Charles Missouri 63304 Recruiting
Alkermes Investigator Site Lincoln Nebraska 68526 Recruiting
Alkermes Investigator Site Omaha Nebraska 68198 Withdrawn
Alkermes Investigator Site Paramus New Jersey 07652 Withdrawn
Alkermes Investigator Site New York New York 10016 Not yet recruiting
Alkermes Investigational Site Kinston North Carolina 28504 Withdrawn
Alkermes Investigator Site Cincinnati Ohio 45219 Recruiting
Alkermes Investigator Site West Chester Ohio 45069 Recruiting
Alkermes Investigator Site DeSoto Texas 75115 Terminated
Alkermes Investigator Site Fort Worth Texas 76104 Withdrawn
Alkermes Investigational Site Richmond Virginia 23220 Recruiting
Alkermes Investigator Site Everett Washington 98201 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05303064, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 5, 2026 · Synced May 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05303064 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →